Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07734766) titled 'Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery' on July 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University
Condition:
Hepato Cellular Carcinoma
Intervention:
Drug: Ebastine
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: October 1, 2026
Target Sample Size: 45
To know more, visit https://clinicaltrials.gov/study/NCT07734766
Disclaimer: Curated by HT Syndica...